We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+45.08%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$930M
AUM Growth
+$84.2M
Cap. Flow
-$119M
Cap. Flow %
-12.76%
Top 10 Hldgs %
65.22%
Holding
58
New
12
Increased
4
Reduced
10
Closed
7

Top Buys

Rank Stock Value
1
RGLS
Regulus Therapeutics
RGLS
+$70.3M
2
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$22M
3
CHRS icon
Coherus Oncology
CHRS
+$21.9M
4
FWP
Forward Pharma A/S American Depositary Shares
FWP
+$20M
5
TGTX icon
TG Therapeutics
TGTX
+$16.7M

Top Sells

Rank Stock Value
1
AVNR
AVANIR PHARMACEUTICALS, INC CL A
AVNR
+$64.2M
2
DYAX
DYAX CORPORATION
DYAX
+$35.8M
3
VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
+$34.8M
4
DVAX
Dynavax Technologies
DVAX
+$17.4M
5
ARAV
Aravive, Inc. Common Stock
ARAV
+$13M

Sector Composition

Rank Sector Weight
1 Healthcare 64.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SCYX icon
26
SCYNEXIS
SCYX
$37.4M
$8.38M 0.9%
10,500
– –
RMTI icon
27
Rockwell Medical
RMTI
$27.2M
$7.26M 0.78%
+6,420
New +$6.58M
AKBA icon
28
Akebia Therapeutics
AKBA
$338M
$6.95M 0.75%
597,363
– –
FRTX
29
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
$6.51M 0.7%
1,969
+231
+13% +$818K
CTIC
30
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$5.9M 0.63%
+250,000
New +$5.78M
ARAV
31
DELISTED
Aravive, Inc. Common Stock
ARAV
$5.19M 0.56%
38,545
-111,287
-74% -$13M
CYTO
32
DELISTED
Altamira Therapeutics Ltd
CYTO
$3.67M 0.39%
12
– –
VXRT
33
DELISTED
Vaxart
VXRT
$3.09M 0.33%
+125,343
New +$3.21M
OCRX
34
DELISTED
Ocera Therapeutics, Inc.
OCRX
$2.66M 0.29%
417,476
– –
TTOO
35
DELISTED
T2 Biosystems, Inc
TTOO
$2.65M 0.29%
28
– –
AGIO icon
36
Agios Pharmaceuticals
AGIO
$2.08B
$1.97M 0.21%
17,600
– –
WGBS
37
DELISTED
WaferGen Bio-systems, Inc.
WGBS
$1.68M 0.18%
112,000
– –
PTCT icon
38
PTC Therapeutics
PTCT
$6.18B
$1.34M 0.14%
25,800
– –
MACK
39
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$1.31M 0.14%
14,794
– –
LUMO
40
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$1.19M 0.13%
3,333
– –
ALKS icon
41
Alkermes
ALKS
$8.11B
$1.12M 0.12%
19,200
– –
REGN icon
42
Regeneron Pharmaceuticals
REGN
$72.9B
$1M 0.11%
2,450
– –
CELG
43
DELISTED
Celgene Corp
CELG
$973K 0.1%
8,700
– –
AMGN icon
44
Amgen
AMGN
$209B
$940K 0.1%
5,900
– –
RGEN icon
45
Repligen
RGEN
$6.91B
$891K 0.1%
45,000
– –
BIIB icon
46
Biogen
BIIB
$30.9B
$883K 0.09%
2,600
– –
ACAD icon
47
Acadia Pharmaceuticals
ACAD
$4.51B
$867K 0.09%
27,300
-2,700
-9% -$76.6K
KERX
48
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$838K 0.09%
59,200
– –
EIGR
49
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$799K 0.09%
+91
New +$528K
KYTH
50
DELISTED
KYTHERA BIOPHARMACEUTICALS, INC COM
KYTH
$789K 0.08%
22,750
– –
1
2
3

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q4 2014 Portfolio in Review

As of Q4 2014, RA Capital Management held 58 positions worth $930M, up 10% from $846M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

RA Capital Management withdrew a net $119M in Q4 2014, closing 7 positions and reducing 10 holdings. Its most notable exit was AVANIR PHARMACEUTICALS, INC CL A, an estimated $64.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, up from 50% a quarter earlier.

Against the trend, RA Capital Management opened a new position in Regulus Therapeutics worth $76.1M.

  • RA Capital Management's largest Q4 2014 buy was Regulus Therapeutics: 39,524 shares worth $76.1M.
  • RA Capital Management added most to TG Therapeutics in Q4 2014, an estimated $16.7M increase.
  • RA Capital Management's biggest Q4 2014 reduction was DYAX CORPORATION, cutting an estimated $35.8M.
  • RA Capital Management fully exited AVANIR PHARMACEUTICALS, INC CL A in Q4 2014, selling an estimated $64.2M.
  • RA Capital Management's ten largest holdings make up 65% of its $930M portfolio in Q4 2014.
  • RA Capital Management opened 12 new positions and closed 7 in Q4 2014.
  • RA Capital Management's portfolio value rose 10% quarter-over-quarter to $930M.

Based on RA Capital Management's 13F filing for Q4 2014, filed 17 Feb 2015.